CSNK2A1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL109221	0.52	10/20
SCHEMBL42421	0.50	10/20
SCHEMBL112200	0.55	9/20
SCHEMBL71021	0.59	6/20
SCHEMBL185452	0.49	6/20
SCHEMBL180521	0.44	6/20
SCHEMBL79794	0.41	6/20
Quercetin (SCHEMBL19723)	1.00	5/20
Quercetin (SCHEMBL118425)	1.00	5/20
SCHEMBL140533	0.51	5/20
SCHEMBL50925	0.43	5/20
SCHEMBL172459	0.39	5/20
SCHEMBL174917	0.39	5/20
Kaempferol (SCHEMBL18817)	1.00	4/20
Myricetin (SCHEMBL19302)	1.00	4/20
Morin (SCHEMBL19984)	1.00	4/20
Chrysin (SCHEMBL44474)	1.00	4/20
Quercetin (SCHEMBL22103)	0.97	4/20
Galangin (SCHEMBL117225)	0.81	4/20
Datiscetin (SCHEMBL43916)	0.78	4/20

Clinical trials — most relevant to CSNK2A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19	PHASE2	COMPLETED
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC	PHASE2	COMPLETED
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Dose-escalation Study of Oral CX-4945	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer	nan	UNKNOWN
Study of a Candidate Gene Involved in Goldenhar Syndrome.	nan	COMPLETED
Study of Metabolic Modifications in Children With Noonan Syndrome	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex	nan	COMPLETED
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization	nan	COMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Clinical Characterization of Frequent Monogenic Forms of Neurodevelopmental Disorders	nan	UNKNOWN
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
PCM1-JAK2 in Therapy Related Neoplasms	nan	UNKNOWN
Family Blood Pressure Program - HyperGEN	nan	COMPLETED
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)	nan	COMPLETED
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CSNK2A1 binder may also engage these)

Protein	Name	Similarity
P33674	—	1.000	P33674 →
P68399	—	1.000	P68399 →
P21868	—	1.000	P21868 →
P28020	—	1.000	P28020 →
P19139	—	1.000	P19139 →
Q60737	—	1.000	Q60737 →
CSNK2A3	Casein kinase II subunit alpha 3 (CK II alpha	1.000	landscape →
O76484	—	0.985	O76484 →
P18334	—	0.983	P18334 →
P08181	—	0.983	P08181 →
B6F107	—	0.980	B6F107 →
Q9AR27	—	0.980	Q9AR27 →
P21869	—	0.979	P21869 →
P28523	—	0.975	P28523 →
O54833	—	0.973	O54833 →
CSNK2A2	Casein kinase II subunit alpha'	0.973	landscape →
P20427	—	0.970	P20427 →
O64817	—	0.970	O64817 →
Q8TG13	—	0.968	Q8TG13 →
Q9DGD9	—	0.965	Q9DGD9 →
O42099	—	0.961	O42099 →
Q90327	—	0.961	Q90327 →
Q08466	—	0.961	Q08466 →
Q08467	—	0.961	Q08467 →
Q9VT57	—	0.960	Q9VT57 →
Q91Y86	—	0.958	Q91Y86 →
E1BMN8	—	0.954	E1BMN8 →
Q17IE8	—	0.954	Q17IE8 →
P40231	—	0.954	P40231 →
Q5N942	—	0.953	Q5N942 →